Navigation Links
ViroPharma Announces Positive CHMP Opinion for Cinryze® (C1 Inhibitor [Human]) in European Union
Date:3/18/2011

as designated an orphan medicinal product on October 8, 2009. Upon granting of a Centralized Marketing Authorization and retention of the orphan medicinal product designation, Cinryze would be entitled to a period of 10 years market exclusivity in respect of the approved therapeutic indication. This 10-year market exclusivity period could be extended cumulatively to 12 years when the results of all studies conducted in compliance with an agreed pediatric investigation plan are completed and included in the summary of product characteristics.

About Cinryze® (C1 esterase inhibitor [human])

Cinryze is a highly purified, pasteurized and nanofiltered plasma-derived C1 esterase inhibitor product.  In the U.S., Cinryze was approved by FDA for routine prophylaxis against angioedema attacks in adolescent and adult patients with HAE.  In the E.U., the recommended indication is for treatment and pre-procedure prevention of angioedema attacks in adults and adolescents with hereditary angioedema (HAE), and routine prevention of angioedema attacks in adults and adolescents with severe and recurrent attacks of hereditary angioedema (HAE), who are intolerant to or insufficiently protected by oral prevention treatments or patients who are inadequately managed with repeated acute treatment.

Severe hypersensitivity reactions to Cinryze may occur.  Thrombotic events have occurred in patients receiving Cinryze for routine prophylaxis, and in patients receiving off-label high dose C1 inhibitor therapy.  Monitor patients with known risk factors for thrombotic events.  With any blood or plasma derived product, there may be a risk of transmission of infectious agents, e.g. viruses and, theoretically, the CJD agent. The risk has been reduced by screening donors for prior exposure to certain virus infections and by manufacturing steps to reduce the risk of viral transmission including pasteurization and nanofiltration.  <
'/>"/>

SOURCE ViroPharma Incorporated
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. ViroPharma to Present at Three Upcoming Healthcare Conferences
2. ViroPharma to Present at the Natixis Bleichroeder Conference
3. ViroPharma To Present at the Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
4. ViroPharma to Release 2008 First Quarter Financial Results on April 30, 2008
5. ViroPharma Announces Discontinuation of HCV-796 Development
6. ViroPharma Announces Completion of Enrollment in Phase 3 Study of Maribavir in Stem Cell Transplant Patients
7. ViroPharma Incorporated Completes Acquisition of Lev Pharmaceuticals
8. ViroPharma Announces Presentation of Cinryze(TM) Data in Acute Treatment of Hereditary Angioedema
9. ViroPharma Announces Discontinuation of Maribavir Phase 3 Study in Liver Transplant Patients
10. ViroPharma Submits Comments on Vancocin(R) Draft Bioequivalence Guidance
11. ViroPharma Incorporated Reports Third Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/22/2014)... , Oct. 22, 2014  With a vision ... health medications, a Global Pharmaceutical and Biotech manufacturer ... technology and turnkey solution to protect their animal ... http://photos.prnewswire.com/prnh/20141021/153438 Photo - ... was serialized and aggregated by the Xyntek and ...
(Date:10/22/2014)... 2014   BioNano Genomics , the genome ... centers to purchase an Irys™ System . Among ... Institute (NCI), NIH Intramural Sequencing Center (NISC) and Genoscope ... a comprehensive view of a genome was a ... not deliver the scalability or reliability to detect ...
(Date:10/22/2014)... Abaxis, Inc. (NasdaqGS: ABAX ), ... today reported financial results for the second fiscal quarter ... , Revenues of $53.9 million, up 18% over ... $0.24, up 33% over last year,s comparable quarter. ... Veterinary Reference Laboratories (AVRL) of $3.5 million, up 50% ...
Breaking Medicine Technology:Xyntek and Antares Serialization Solution Protects Pets Too! 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 2BioNano's Irys System Adopted by Leading Genomics Centers for Comprehensive Detection of Human Genome Structural Variation 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 2Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 3Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 4Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 5Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 6Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 7Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 8Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 9Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 10Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 11Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 12Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 13Abaxis Reports Record Revenues for the Second Quarter of Fiscal 2015 14
... and local dignitaries ushered in a new chapter in ... of a laboratory complex designed to speed up cures ... housing 78 labs and other facilities, signifies a break ... different fields and allowing them to communicate more effectively. ...
... Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN ... a new study examining the immunogenicity and safety profiles of ... and younger adults to a standard dose of Fluzone vaccine. ... the Infectious Diseases Society of America on October 21, 2011. ...
Cached Medicine Technology:MUSC Dedicates New Bioengineering and Drug Discovery Hubs 2Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 2Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 3Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 4Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 5Sanofi Pasteur Presents New Data Confirming Fluzone® High-Dose (Influenza Virus Vaccine) Produces Higher Antibody Response in the Age 65+ Population 6
(Date:10/22/2014)... October 22, 2014 Akeso Biomedical, ... for the treatment of bacterial infections, microbial biofilms, and ... joined its board of directors. , Dr. ... Systems at The Massachusetts Institute of Technology, or MIT. ... since 1968. Dr. Sinskey also holds positions as Co-Director ...
(Date:10/22/2014)... Two sisters in high school have developed ways to ... Krishen use electronic stethoscopes, which electronically amplify body sounds, ... or heartbeats. Ilina, a senior at Port Huron ... way to detect early lung damage in people exposed ... recorded one breath cycle each from 16 smokers, 25 ...
(Date:10/22/2014)... 21, 2014 (HealthDay News) -- Measures taken by Firestone ... Ebola-ravaged Liberia may have limited the spread of the ... The Firestone Natural Rubber Co. provides health services ... of nearby densely populated communities. Between Aug. 1 ... Ebola cases among those 80,000 people. That incidence rate ...
(Date:10/20/2014)... October 20, 2014 The newly updated ... source of thousands of facts, figures and forecasts on ... 68 medical sector forecast categories the Worldwide Medical ... regional and national views on the worldwide medical market ... The report gives you data for 2010-2019, covering each ...
(Date:10/20/2014)... The Advocator Group, LLC is proud ... for Suicide Prevention’s (AFSP) Out of the Darkness walk ... that hosts hundreds of community walks throughout the country ... to help understand and prevent suicide through not only ... , The Advocator Group shares this passion for ...
Breaking Medicine News(10 mins):Health News:Akeso Biomedical Appoints Dr. Anthony J. Sinskey to Board of Directors 2Health News:Teen Sisters Develop Ways to Measure Lung, Heart Damage 2Health News:Tire Company Sets Standard for Ebola Care in Liberia: CDC 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 2Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 3Health News:Worldwide Medical Market Forecasts to 2019 a New Research Report Added to ReportsnReports.com 4Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 2Health News:The Advocator Group, LLC is Proud to Participate in an Out of the Darkness Community Walk, October 25th, to Increase Suicide Awareness 3
... improved sleep for patients with chronic neck or back ... interfered with their daily functioning, according to a study ... study, published online by the journal Sleep Medicine, ... who already are taking medications for pain and might ...
... , OMAHA, Neb. , Feb. 11 ... dental technology developed to improve human dental health for two ... Cleaning Paste and the Petrodex® Tooth-Hugger Toothbrush. The Petrodex Tooth-Hugger ... Petrodex Ultra Advanced Veterinary Cleaning Paste will be available in ...
... , Idiopathic Pulmonary Fibrosis (IPF) ... SAN JOSE, Calif. , Feb. 11 ... Commissioner Michael Astrue ,s announcement this morning via press ... Fibrosis (PF), and a listing of 37 other diseases and ...
... PITTSBURGH, Feb. 11 Patients admitted to hospitals with ... hospitals with low-intensity approaches, according to a University of ... issue of the journal Medical Care. Higher-intensity care refers ... admission, intubation or mechanical ventilation, kidney dialysis and feeding ...
... finds less than 1% use it as preventative; experts say drug ... -- Only a tiny fraction of women at high risk of ... This news comes despite the fact that experts have known since ... by almost 50 percent. , "This is not a surprise to ...
... ... FAB-HOMES ™, a green home design studio based in Vancouver, Canada, is ... market. Fab-homes™ showcases a selection of modern, European dwellings planned along the ... 90% less energy for heating, cooling and building operation than a standard ...
Cached Medicine News:Health News:Behavioral therapy improves sleep and lives of patients with pain 2Health News:Human Dental Technology Leads to Breakthroughs for Pet Dental Health at Sergeant's Pet Care Products, Inc. 2Health News:Human Dental Technology Leads to Breakthroughs for Pet Dental Health at Sergeant's Pet Care Products, Inc. 3Health News:Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration 2Health News:Patients with Lethal Lung Disease Finally Receive Recognition by Social Security Administration 3Health News:Survival benefit with high-intensity end-of-life approaches 2Health News:Few Women at High Risk for Breast Cancer Take Tamoxifen 2Health News:Few Women at High Risk for Breast Cancer Take Tamoxifen 3Health News:FAB-HOMES&#8482; Presents First Passive House Collection 2Health News:FAB-HOMES&#8482; Presents First Passive House Collection 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: